HLS Therapeutics Inc.
HLTRF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $13,511 | $14,171 | $12,623 | $15,542 |
| % Growth | -4.7% | 12.3% | -18.8% | – |
| Cost of Goods Sold | $2,537 | $2,505 | $2,398 | $2,685 |
| Gross Profit | $10,974 | $11,666 | $10,225 | $12,857 |
| % Margin | 81.2% | 82.3% | 81% | 82.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $2,896 | $2,549 | $2,790 | $2,746 |
| SG&A Expenses | $5,565 | $5,595 | $5,620 | $6,184 |
| Sales & Mktg Exp. | $2,669 | $3,046 | $2,830 | $3,438 |
| Other Operating Expenses | $6,783 | $6,849 | $6,796 | $9,713 |
| Operating Expenses | $12,348 | $12,444 | $12,416 | $15,897 |
| Operating Income | -$1,374 | -$778 | -$2,191 | -$3,040 |
| % Margin | -10.2% | -5.5% | -17.4% | -19.6% |
| Other Income/Exp. Net | -$2,561 | -$1,721 | -$2,268 | $102 |
| Pre-Tax Income | -$3,935 | -$2,499 | -$4,459 | -$2,938 |
| Tax Expense | -$17 | $242 | -$23 | $85 |
| Net Income | -$3,918 | -$2,741 | -$4,436 | -$3,023 |
| % Margin | -29% | -19.3% | -35.1% | -19.5% |
| EPS | -0.12 | -0.087 | -0.14 | -0.095 |
| % Growth | -38.6% | 38.1% | -47.5% | – |
| EPS Diluted | -0.12 | -0.088 | -0.14 | -0.095 |
| Weighted Avg Shares Out | 31,403 | 31,641 | 31,793 | 31,793 |
| Weighted Avg Shares Out Dil | 31,403 | 31,641 | 31,793 | 31,793 |
| Supplemental Information | – | – | – | – |
| Interest Income | $24 | $33 | $32 | $35 |
| Interest Expense | $2,445 | $1,733 | $2,018 | $2,299 |
| Depreciation & Amortization | $5,511 | $5,483 | $5,360 | $5,434 |
| EBITDA | $4,021 | $4,717 | $2,919 | $4,795 |
| % Margin | 29.8% | 33.3% | 23.1% | 30.9% |